Aptevo Therapeutics Inc. APVO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

50/100

2/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Aptevo Therapeutics Inc. (APVO) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -193,202.53%, forward earnings yield 357.14%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E 0.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -193,202.53%).
Forward P/E 0.3 — analysts expect a return to profitability with estimated EPS of $19.51 for FY2030.
Trailing Earnings Yield -193,202.53% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 357.14% as earnings recover.

Overall SharesGrow Score: 47/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

50/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

11/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — APVO

Valuation Multiples

P/E (TTM)0.0

Forward P/E0.3

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.4

Per Share Data

EPS (TTM)$-8,230.43

Forward EPS (Est.)$19.51

Book Value / Share$5,509.03

Revenue / Share$0.00

FCF / Share$-8,111.57

Yields & Fair Value

Earnings Yield-193,202.53%

Forward Earnings Yield357.14%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	0.0	0.00	0.00	0.00	-
2017	0.0	0.00	0.00	0.00	-
2018	0.0	0.00	0.00	0.00	-
2019	0.0	0.00	0.00	0.00	-
2020	-7.0	0.07	7.49	28.84	-
2021	-1.3	0.04	30.34	3.00	-
2022	1.5	-0.01	0.66	3.80	-
2023	-0.1	0.00	0.18	0.00	-
2024	0.0	0.00	0.25	0.00	-
2025	0.0	0.00	0.00	0.00	5,280.38%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-3,418.80	$36.43M	$-112.42M	-308.5%
2017	$-1,320.17	$14.66M	$6.97M	47.6%
2018	$-1,469.88	$23.07M	$-53.69M	-232.8%
2019	$-9,439.02	$32.42M	$-40.45M	-124.7%
2020	$-416.37	$4.31M	$-18.45M	-428.1%
2021	$-267.09	$12.29M	$-27.31M	-222.2%
2022	$2,555.96	$3.11M	$8.03M	257.8%
2023	$-62.62	$0.00	$-17.41M	-
2024	$-84.67	$0.00	$-24.13M	-
2025	$-87.27	$0.00	$-25.97M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-20.99	$-20.99 – $-20.99	$7.55M	$7.55M – $7.55M	1
2027	$-18.65	$-18.65 – $-18.65	$6.74M	$6.74M – $6.74M	1
2028	$-18.04	$-18.04 – $-18.04	$17.74M	$17.74M – $17.74M	1
2029	$-1.97	$-1.97 – $-1.97	$22.87M	$22.87M – $22.87M	1
2030	$19.51	$19.51 – $19.51	$70.22M	$70.22M – $70.22M	1